Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has a diagnosis of RA based upon the American College of Rheumatology (ACR) 1987 Revised Criteria.~* The patient must have had an inadequate response to methotrexate and have active disease, as defined by both: ≥6 joints tender or painful on motion; and ≥6 joints swollen; and fulfills 1 of the following 2 criteria at Screening: 1.ESR (Westergren method) \>28 mm in the local laboratory. 2. CRP \>7 mg/L in the central laboratory.~* No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis.~* The patient must have been on a stable dose of 7.5 mg to 25 mg weekly of methotrexate and washed out of all other DMARDs.~Exclusion Criteria:~* Blood dyscrasias including confirmed: 1. Hemoglobin \<9 g/dL or Hematocrit \<30%; 2. White blood cell count \<3,000 cu.mm. Absolute neutrophil count \<1,200 cu.mm; 4. Platelet count \<100,000/L~* History of any other autoimmune rheumatic disease other than Sjogren's syndrome~* No malignancy or history of malignancy.~* History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug~* Patients who have failed any TNFi for either lack of efficacy or a TNFi mechanism related adverse event.~* Patients who have previously received adalimumab therapy for any reason.~* Patients who are contraindicated for treatment with adalimumab in accordance with the approved local label.~* Patients meeting the New York Heart Association Class III and Class IV Congestive Heart failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5mg (Type: EXPERIMENTAL): None
- 10 mg (Type: EXPERIMENTAL): None
- Placebo Sequence 1 (Type: PLACEBO_COMPARATOR): None
- Placebo Sequence 2 (Type: PLACEBO_COMPARATOR): None
- adalimumab (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).